OverviewChartNewsTraderScreen

UniCredit Call 82 SNW 19.06.2024/  DE000HD4YZR0  /

Frankfurt Zert./HVB
2024-05-27  1:09:09 PM Chg.-0.030 Bid9:09:04 PM Ask2024-05-27 Underlying Strike price Expiration date Option type
0.770EUR -3.75% -
Bid Size: -		 -
Ask Size: -		 SANOFI SA INHABER ... 82.00 - 2024-06-19 Call
GlobeNewswire 1:00 PM CytoSorbents STAR Registry Data on Patients on Ticagrelor Undergoing CABG Surgery with CytoSorb Pres...
GlobeNewswire 12:00 PM FutureBrand Consumer Index Reveals Brands Are Missing Key Growth Opportunities and Falling Short on ...
GlobeNewswire 06-03 Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival ...
GlobeNewswire 05-31 Press Release: Sanofi launches 2024 global Employee Stock Purchase Plan
GlobeNewswire 05-31 Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
GlobeNewswire 05-31 Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD
GlobeNewswire 05-31 Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type ...
GlobeNewswire 05-31 Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with typ...
GlobeNewswire 05-30 Press Release: Sanofi completes acquisition of Inhibrx, Inc.
GlobeNewswire 05-27 Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible ...
GlobeNewswire 05-23 CRISPR Therapeutics Strengthens Executive Leadership Team with Key Appointments
GlobeNewswire 05-21 Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration
GlobeNewswire 05-20 Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS...
GlobeNewswire 05-20 Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ...
GlobeNewswire 05-20 Shah Capital Withdraws Proxy Campaign Against Re-Election of Directors at Novavax’s 2024 Annual Meet...
GlobeNewswire 05-13 Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 20...
GlobeNewswire 05-13 Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Developme...
TeleTrader 05-13 Europe mixed at open as CPI prints loom
GlobeNewswire 05-13 Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chroni...
TeleTrader 05-10 Novavax skyrockets 213.5% in premarket, highest in 16 months
TeleTrader 05-10 Novavax soars 39.6% in premarket after Sanofi license deal
GlobeNewswire 05-10 Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVI...
GlobeNewswire 05-09 Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab
TeleTrader 05-09 Europe opens mixed with BoE in focus
GlobeNewswire 05-08 IGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate Update